Jane Street’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Jane Street’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-42,378	Closed	-$113K	–	10488
2024 Q1	$113K	Sell	42,378 -34,887	-45%	-$86.4K	﹤0.01%	8488
2023 Q4	$183K	Buy	77,265 +52,750	+215%	+$93.4K	﹤0.01%	8281
2023 Q3	$34.3K	Sell	24,515 -106,978	-81%	-$257K	﹤0.01%	8226
2023 Q2	$398K	Buy	131,493 +115,082	+701%	+$444K	﹤0.01%	6667
2023 Q1	$103K	Buy	16,411 +3,842	+31%	+$23.4K	﹤0.01%	8211
2022 Q4	$76.7K	Buy	+12,569	New	+$102K	﹤0.01%	8225
2022 Q3	–	Sell	-11,636	Closed	-$147K	–	10705
2022 Q2	$147K	Buy	+11,636	New	+$108K	﹤0.01%	8426
2021 Q1	–	Sell	-6,049	Closed	-$241K	–	9717
2020 Q4	$241K	Buy	+6,049	New	+$243K	﹤0.01%	6722

Jane Street's KNTE Position: Q2 2024 in Review

Jane Street sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 42,378 shares — an estimated $113K sold.

Jane Street first reported a position in KNTE in Q4 2020 and held it in 8 quarters. The position peaked at $398K in Q2 2023. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Jane Street reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Jane Street sold 42,378 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $113K.
Jane Street first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Jane Street's Kinnate Biopharma Inc. Common Stock position peaked at $398K in Q2 2023.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Jane Street's 13F filing for Q2 2024, filed 15 Aug 2024.